AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT05033431
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
Phase 1
Terminated
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: [14C]Adavosertib
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2
- Registration Number
- NCT05008913
- Locations
- π¬π§
Research Site, Manchester, United Kingdom
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 2
Completed
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT05008055
- Locations
- π¬π§
Research Site, Sutton, United Kingdom
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
Phase 3
Terminated
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- Biological: Placebo to Benralizumab
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05006573
- Locations
- π»π³
Research Site, Hochiminh, Vietnam
Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Anifrolumab
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT05001698
- Locations
- π¨π³
Research Site, Shanghai, China
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumours
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT04999969
- Locations
- πͺπΈ
Research Site, Pamplona, Spain
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Phase 4
Terminated
- Conditions
- Hyperkalaemia
- Interventions
- Other: Standard dietary advice including K+ restriction.Drug: Sodium Zirconium Cyclosilicate (SZC)Other: Enhanced dietary advice
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT04997161
- Locations
- πΊπΈ
Research Site, West Palm Beach, Florida, United States
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 199
- Registration Number
- NCT04995523
- Locations
- π¬π§
Research Site, Manchester, United Kingdom
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT04994106
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)Drug: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04991571
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
Β© Copyright 2025. All Rights Reserved by MedPath